Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Radiation, Biologic therapy.

Institut Claudius Regaud, Toulouse, France.

Survival: monthsCountry:France
Toxiciy Grade:3City/State/Province:Toulouse
Treatments:Radiation, Biologic therapyHospital:Institut Claudius Regaud
Drugs:Journal:Link
Date:Apr 2013

Description:

Patients:
This phase 2 study involved 27 newly diagnosed glioblastoma patients who had not been previously treated. The median patient age was 59 years and 18 were male.

Treatment:
Patients were treated with radiation therapy and the biologic therapy agent tipifarnib, which is an inhibitor of a protein called farnesyltransferase and may help to lessen cancer cell resistance to radiation.

Toxicities:
The most severe toxicities were of grade 3 and included skin rash, neurologic disorders (seizure and speech impairment), and pain.

Results:
The median overall survival was 18.5 months.

Support:
This study was supported by the pharmaceutical company Janssen-Cilag.

Correspondence: Dr. Elizabeth Cohen-Jonathan Moyal; email: [email protected]



Back